FDA
-
-
-
-
-
-
-
Precision BioSciences begins patient enrollment in DMD gene editing trial
-
-
-
-
-
-
-
iECURE Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of ECUR-506 Ahead of Planned BLA Submission
-
-
-
-
-
-
-
Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event
-
-
-
-
-
-
-
Precision BioSciences shows positive early results for hepatitis B gene therapy
-
-
-
-
-
-
-
Precision BioSciences (DTIL) Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy
-
-
-
-
-
-
-
Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025
-
-
-
-
-
-
-
Precision BioSciences (DTIL) Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency
-
322,240 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

